Compare Biogen Inc (BIIB) vs Ishares Msci Brazil ETF (EWZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Ishares Msci Brazil ETF — how do they compare? Biogen Inc trades at $197.24 (market cap $28.34B), while Ishares Msci Brazil ETF trades at $35.9. The key difference: Biogen Inc is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | EWZ | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $41.75 |
52-Week Low | $122.68 | $26.52 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
EWZ, the iShares MSCI Brazil ETF, trades at $35.39, down 1.5% for the day, with a bullish technical signal driven by moving averages. The ETF has gained approximately 11% year-to-date, supported by Brazil's monetary easing cycle and commodity strength. Recent news highlights its exposure to Latin America's equity rally and potential from Brazil's $10 billion Eco Invest auction aimed at sustainable technologies.
The outlook for EWZ is positive, with upside from Brazil's rate cuts and commodity markets, but risks include dependence on volatile commodity prices and potential derailment of the easing cycle. The ETF offers a discounted entry to Brazilian equities, yet payout consistency is a concern due to its concentrated holdings in firms like Petrobras and Vale.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →
